TY - JOUR
T1 - 18F-ZW-104
T2 - A new radioligand for imaging neuronal nicotinic acetylcholine receptors - In vitro binding properties and PET studies in baboons
AU - Valette, Héric
AU - Xiao, Yingxiang
AU - Peyronneau, Marie Anne
AU - Damont, Annelaure
AU - Kozikowski, Alan P.
AU - Wei, Zhi Liang
AU - Kassiou, Michael
AU - Kellar, Kenneth J.
AU - Dollé, Frédéric
AU - Bottlaender, Michel
PY - 2009/8/1
Y1 - 2009/8/1
N2 - An extensive series of radioligands has been developed for imaging central nicotinic acetylcholine receptors (nAChRs) with PET. Two halogeno-derivatives of A-85380 are being used in humans. Nevertheless, these derivatives still display too-slow brain kinetics and low signal-to-noise ratio. Methods: A novel nAChR radioligand, 5-(6-fluorohexyn-1-yl)-3-[2(S)-2-azetidinylmethoxy]pyridine (ZW-104), was characterized in vitro using competition binding assays (nAChR subtypes heterologously expressed in HEK 293 cells and in native α4β2 nAChRs from rat brain). 18F-ZW-104 was prepared as follows: no-carrier-added nucleophilic aliphatic radiofluorination of the corresponding N-Boc-protected tosyloxy derivative 5-(6-tosyloxyhexyn-1-yl)-3-[2(S)-(N-(tert- butoxycarbonyl))-2-azetidinylmethoxy] pyridine) with the activated 4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo-[8,8,8]hexacosane (K- 18F-F-Kryptofix 222 [K222] complex), followed by quantitative trifluoroacetic acid-induced removal of the N-Boc protective group. 18F-ZW-104 was then studied in baboons using PET. Results: ZW-104 showed high binding affinities for rat α4β2 nAChRs (Ki, 0.2 nM) and other subtypes containing the β2 subunit but much lower affinities for rat α3β4 nAChRs (Ki, 5,500 nM) and other subtypes containing the β4 subunit. The regional radioactivity distribution in the baboon brain matched that of the α4β2 nAChR, which was similar to that of 2-18F-fluoro-3-(2(S)-azetidinylmethoxy) pyridine (2-18F-A-85380), a radioligand used in humans. Comparison between 18F-ZW-104 and 2-18F-A-85380 demonstrated better in vivo binding properties of the new radioligand: a substantially greater amount of radioactivity accumulated in the brain, and the occurrence of peak uptake in the thalamus was earlier than that of 2-18F-A-85380 and was followed by washout. Distribution volume values in different brain regions were 2-fold higher for 18F-ZW-104 than for 2-18F-A-85380. Displacement by nicotine or unlabeled ZW-104 demonstrated a lower nonspecific binding than that of 2-F-A-85380. Conclusion: These results suggest that 18F-ZW- 104 is a promising PET radioligand for studying nAChRs containing the β2 subunits in humans.
AB - An extensive series of radioligands has been developed for imaging central nicotinic acetylcholine receptors (nAChRs) with PET. Two halogeno-derivatives of A-85380 are being used in humans. Nevertheless, these derivatives still display too-slow brain kinetics and low signal-to-noise ratio. Methods: A novel nAChR radioligand, 5-(6-fluorohexyn-1-yl)-3-[2(S)-2-azetidinylmethoxy]pyridine (ZW-104), was characterized in vitro using competition binding assays (nAChR subtypes heterologously expressed in HEK 293 cells and in native α4β2 nAChRs from rat brain). 18F-ZW-104 was prepared as follows: no-carrier-added nucleophilic aliphatic radiofluorination of the corresponding N-Boc-protected tosyloxy derivative 5-(6-tosyloxyhexyn-1-yl)-3-[2(S)-(N-(tert- butoxycarbonyl))-2-azetidinylmethoxy] pyridine) with the activated 4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo-[8,8,8]hexacosane (K- 18F-F-Kryptofix 222 [K222] complex), followed by quantitative trifluoroacetic acid-induced removal of the N-Boc protective group. 18F-ZW-104 was then studied in baboons using PET. Results: ZW-104 showed high binding affinities for rat α4β2 nAChRs (Ki, 0.2 nM) and other subtypes containing the β2 subunit but much lower affinities for rat α3β4 nAChRs (Ki, 5,500 nM) and other subtypes containing the β4 subunit. The regional radioactivity distribution in the baboon brain matched that of the α4β2 nAChR, which was similar to that of 2-18F-fluoro-3-(2(S)-azetidinylmethoxy) pyridine (2-18F-A-85380), a radioligand used in humans. Comparison between 18F-ZW-104 and 2-18F-A-85380 demonstrated better in vivo binding properties of the new radioligand: a substantially greater amount of radioactivity accumulated in the brain, and the occurrence of peak uptake in the thalamus was earlier than that of 2-18F-A-85380 and was followed by washout. Distribution volume values in different brain regions were 2-fold higher for 18F-ZW-104 than for 2-18F-A-85380. Displacement by nicotine or unlabeled ZW-104 demonstrated a lower nonspecific binding than that of 2-F-A-85380. Conclusion: These results suggest that 18F-ZW- 104 is a promising PET radioligand for studying nAChRs containing the β2 subunits in humans.
KW - Central nicotinic receptors
KW - In vitro binding
KW - Positron emission tomography
KW - β2 subunit
UR - http://www.scopus.com/inward/record.url?scp=68249135109&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=68249135109&partnerID=8YFLogxK
U2 - 10.2967/jnumed.108.061374
DO - 10.2967/jnumed.108.061374
M3 - Article
C2 - 19652217
AN - SCOPUS:68249135109
SN - 0161-5505
VL - 50
SP - 1349
EP - 1355
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 8
ER -